Exhibit 12.1
OncoGenex Pharmaceuticals, Inc.
Statement of Computation of Ratio of Earnings to Fixed Charges
|
Fiscal Year Ended December 31, |
Nine Months Ended September 30, 2012 |
|||||||||||||||||||||||
| (In $000’s, except ratio) |
2007 | 2008 | 2009 | 2010 | 2011 | |||||||||||||||||||
| Fixed Charges: |
||||||||||||||||||||||||
| Interest expense |
$ | 193 | $ | 749 | $ | 1,251 | $ | 1,172 | $ | 1,086 | $ | 744 | ||||||||||||
| Amortized premiums, discounts and capitalized expenses related to indebtedness |
2,944 | 1,973 | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| $ | 3,137 | $ | 2,722 | $ | 1,251 | $ | 1,172 | $ | 1,086 | $ | 744 | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Earnings (loss): |
||||||||||||||||||||||||
| Net loss before income tax benefit (provision) |
$ | (7,823 | ) | $ | (10,691 | ) | $ | (2,465 | ) | $ | (15,584 | ) | $ | (14,673 | ) | $ | (16,995 | ) | ||||||
| Add fixed charges |
3,137 | 2,722 | 1,251 | 1,172 | 1,086 | 744 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| $ | (4,686 | ) | $ | (7,969 | ) | $ | (1,214 | ) | $ | (14,412 | ) | $ | (13,587 | ) | $ | (16,251 | ) | |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Ratio of earnings to fixed charges |
— | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Deficiency of earnings to fixed charges |
$ | (7,823 | ) | $ | (10,691 | ) | $ | (2,465 | ) | $ | (15,584 | ) | $ | (14,673 | ) | $ | (16,995 | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||